Campus Construction Update

Starting September 14, we’re closing the Menino building lobby entrance. This, along with the ongoing Yawkey building entrance closure, will help us bring you an even better campus experience that matches the exceptional care you've come to expect. Please enter the Menino and Yawkey buildings through the Moakley building, and make sure to leave extra time to get to your appointment. Thank you for your patience. 

Click here to learn more about our campus redesign. 

Funded Programs for HIV and HCV Research

The Pediatric Infectious Disease group has a well-established collaboration with the Department of Obstetrics, and we have a number of programs involving the health of mothers and babies. Active research studies regarding treatment of pregnant HIV infected women and the prevention of vertical transmission are ongoing.

In addition we have recently developed a research agenda regarding Hepatitis C infected women and the potential risk to their newborns from this maternal exposure. Our first epidemiological studies are up and running. Now that therapeutic options have expanded, we now plan on looking at the advantage and possibility of early diagnosis in the infants. 

Targeting HIV Infection:

Boston Medical Center is currently the only institution in. New England who is part of the IMPAACT Network, a group of domestic and international academic sites conducting clinical trials important to the care of HIV infected infants, children, adolescents, and pregnant women. Considered a Center of Excellence, we have been part of this important research network for over 25 years._.  We have participated in cutting edge research including the first studies to show interruption of the vertical transmission of HIV from mother to baby, and we continue to have uninterrupted access to the latest state of the art therapeutics and diagnostics. We are currently conducting research of investigational drugs and vaccines for both primary HIV therapy and the prevention and treatment of opportunistic infections and the long term complications of HIV infection.

In addition to the NIH funded clinical trials we have several ongoing industry-sponsored trials, targeting the special population of children and adolescents with resistant HIV infection